Novartis International AG is a Swiss multinational pharmaceutical company based in Basel, Switzerland. It is one of the largest pharmaceutical companies in the world.
Bristol Myers Squibb (BMS) is an American pharmaceutical company, headquartered in New York City.
Qinetiq is a British multinational defence technology company headquartered in Farnborough, Hampshire. It is the world's 52nd-largest defence contractor measured by 2011 defence revenues, and the sixth-largest based in the UK.
Pharmacia & Upjohn was a global pharmaceutical company formed by the merger of Sweden-based Pharmacia AB and the American company Upjohn in 1995. Today the remainder of the company is owned by Pfizer. In 1997, Pharmacia & Upjohn sold several brands to Johnson & Johnson, including Motrin and Cortaid.
Ajay Piramal is an Indian billionaire industrialist, and the chairman of the Piramal Group, a conglomerate with interests in pharmaceutical, financial services, real estate, healthcare analytics and glass packaging. Piramal Enterprises has 3 major businesses – Pharma, Financial Services and Healthcare Insights & Analytics.
Bevacizumab, sold under the brand name Avastin, is a medication used to treat a number of types of cancers and a specific eye disease. For cancer it is given by slow injection into a vein (intravenous) and used for colon cancer, lung cancer, glioblastoma, and renal-cell carcinoma. For age-related macular degeneration it is given by injection into the eye (intravitreal).
MoD Boscombe Down(ICAO: EGDM) is the home of a military aircraft testing site, located near the town of Amesbury in Wiltshire, England. The site is currently run, managed and operated by QinetiQ, the private defence company created as part of the breakup of the Defence Evaluation and Research Agency (DERA) in 2001 by the UK Ministry of Defence (MoD). It is also the home of the Empire Test Pilots' School (ETPS).
Astellas Pharma Inc. is a Japanese multinational pharmaceutical company, formed on 1 April 2005 from the merger of Yamanouchi Pharmaceutical Co., Ltd. and Fujisawa Pharmaceutical Co., Ltd.. On February 5, 2020, the company announced management changes effective from April 1, 2020.
Beximco Pharmaceuticals Ltd also known as Beximco Pharma, is a pharmaceutical company in Bangladesh. It is part of the Beximco Group of Companies.
Malvern Hills Science Park is located in Malvern, Worcestershire, England. It is a partnership between a number of partners including: QinetiQ, Malvern Hills District Council, Worcestershire County Council, and the West Midlands Regional Development Agency, making a total of around 40 companies as of 2019.
Oxford Biomedica is a gene and cell therapy company specialising in the development of gene-based medicines. It is listed on the London Stock Exchange and is a constituent of the FTSE 250 Index.
Medidata Solutions is an American technology company that develops and markets software as a service (SaaS) for clinical trials. These include protocol development, clinical site collaboration and management; randomization and trial supply management; capturing patient data through web forms, mobile health (mHealth) devices, laboratory reports, and imaging systems; quality monitor management; safety event capture; and monitoring and business analytics. Headquartered in New York City, Medidata has locations in China, Japan, Singapore, South Korea, the United Kingdom, and the United States.
Arie S. Belldegrun, FACS, is an Israeli-American urologic oncologist, businessman, and investor.
Daqo New Energy Corp. is a Chinese company engaged in the manufacture of monocrystalline silicon (mono-Si) and polysilicon (poly-Si), primarily for use in solar photovoltaic systems. The company operates a mono-Si and poly-Si manufacturing facility located in Shihezi, Xinjiang Province, China. Daqo formerly manufactured silicon wafers at a facility in Chongqing, China and photovoltaic modules at a facility in Nanjing, China.
Horizon Therapeutics plc is a biopharmaceutical company focused on researching, developing, and commercializing medicines that address critical needs for people impacted by rare and rheumatic diseases. Horizon primarily markets products in the United States, which represented 97% of Horizon's 2019 worldwide sales. In 2014 Horizon executed a tax inversion to move its legal headquarters to Ireland to avail of Ireland's low tax rates and beneficial corporate tax system. On May 2, 2019 shareholders of the company approved the change of the company's name to Horizon Therapeutics plc.
ADVANZ PHARMA Corp. is a multi-national pharmaceutical company headquartered in London. It changed its name from Concordia Healthcare Corp. in November 2018. The company focuses on a number of therapy areas including endocrinology, ophthalmology, urology, anti-infectives, pain management, central nervous system disorders, oncology, haematology, cardiology and intensive care medicine. The company also focuses on acquiring legacy pharmaceutical compounds which are usually off patent. ADVANZ PHARMA is a global pharmaceutical company with its operational headquarters in London, UK, operations centre in Mumbai, India and regional hubs in Europe, Australia and the US.
Hanwha Q Cells Co., Ltd., and "Hanwha Q Cells & Advanced Materials Corp.", commonly known as Q Cells or Hanwha Q Cells, are manufacturers of photovoltaic (PV) solar cells. They are headquartered in Seoul, South Korea. Its technology and innovation center is located in Thalheim, Germany. Both companies are subsidiaries of Hanwha Chemical, an affiliate of the Hanwha Group. The companies operate under brand Q Cells. CEO of the company is Hee Cheul (Charles) Kim.
Veritas Capital is a New York-based private-equity firm founded in 1992 that invests in companies that provide critical products and services, primarily technology-enabled products and services, to government and commercial customers worldwide. The firm’s first fund closed in 1998. They closed a seventh fund in 2019; in all, Veritas has approximately $20 billion of assets under management. Veritas is led by Ramzi Musallam, the firm’s Chief Executive Officer and Managing Partner.
ICON is an Irish-headquartered developer of drugs to the pharmaceutical, biotechnology and medical device industries. ICON offers consulting, clinical development and commercialisation services in a broad range of therapeutic areas from a global network of offices. As of September 2020, ICON had 15,250 employees in 94 locations spread across 40 countries.
